{"id":"rhgh-norditropine-simplexx","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Carpal tunnel syndrome"},{"rate":null,"effect":"Fluid retention"},{"rate":null,"effect":"Arthralgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"rhGH activates the growth hormone receptor, a transmembrane receptor that triggers intracellular signaling cascades promoting anabolic effects including increased protein synthesis, lipolysis, and insulin-like growth factor-1 (IGF-1) production. This leads to increased linear growth in children, enhanced muscle mass, reduced fat mass, and improved metabolic function in both pediatric and adult populations.","oneSentence":"Recombinant human growth hormone (rhGH) binds to growth hormone receptors on target cells to stimulate growth, metabolism, and protein synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:02.057Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Growth hormone deficiency in children"},{"name":"Growth hormone deficiency in adults"},{"name":"Short stature in children born small for gestational age"},{"name":"Turner syndrome"},{"name":"Chronic kidney disease-related growth failure"}]},"trialDetails":[{"nctId":"NCT00597480","phase":"PHASE4","title":"Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-01","conditions":"Small for Gestational Age","enrollment":10},{"nctId":"NCT01626833","phase":"PHASE2, PHASE3","title":"Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-03","conditions":"Anorexia Nervosa, Interruption of Growth, Delayed Puberty","enrollment":15},{"nctId":"NCT01973244","phase":"PHASE1","title":"A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-16","conditions":"Growth Hormone Disorder, Growth Hormone Deficiency in Children","enrollment":32},{"nctId":"NCT00567385","phase":"PHASE4","title":"Liquid Somatropin Formulation in Children With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-03-10","conditions":"Growth Hormone Disorder, Growth Hormone Deficiency in Children","enrollment":176},{"nctId":"NCT01034202","phase":"PHASE1","title":"Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-08","conditions":"Growth Hormone Disorder, Healthy","enrollment":56},{"nctId":"NCT01502137","phase":"PHASE1","title":"Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-06","conditions":"Chronic Kidney Disease, End-Stage Renal Disease, Healthy","enrollment":21},{"nctId":"NCT00254514","phase":"PHASE2","title":"Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone in Tibia Fractures","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-08","conditions":"Bone Fracture, Tibia Fractures","enrollment":407},{"nctId":"NCT00184678","phase":"PHASE3","title":"Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-02","conditions":"Growth Hormone Disorder, Adult Growth Hormone Deficiency","enrollment":161},{"nctId":"NCT01090778","phase":"PHASE2","title":"Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2010-10","conditions":"Growth Hormone Deficiency","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"rhGH (Norditropine SimpleXx®)","genericName":"rhGH (Norditropine SimpleXx®)","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant human growth hormone (rhGH) binds to growth hormone receptors on target cells to stimulate growth, metabolism, and protein synthesis. Used for Growth hormone deficiency in children, Growth hormone deficiency in adults, Short stature in children born small for gestational age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}